-
Something wrong with this record ?
The role of neoadjuvant chemotherapy and surgery in cervical cancer
H. Robova, M. Halaska, M. Pluta, P. Skapa, P. Strnad, J. Lisy, L. Rob
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Chemotherapy, Adjuvant MeSH
- Fertility MeSH
- Hysterectomy MeSH
- Carcinoma drug therapy pathology surgery MeSH
- Middle Aged MeSH
- Humans MeSH
- Uterine Cervical Neoplasms drug therapy pathology surgery MeSH
- Neoadjuvant Therapy MeSH
- Retrospective Studies MeSH
- Neoplasm Staging MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
The role of neoadjuvant chemotherapy (NAC) in "bulky" and locally advanced cervical cancer has been of interest for the last 25 years, and in many countries, NAC has become the standard of care. In the present paper, we review our 10 years' experience with high-dose-density NAC in cervical cancer management in 141 women (CervNAC I protocol). High-dose-density neoadjuvant chemotherapy and radical surgery has resulted in high clinical response rates and seems to be feasible in the management of stage IB bulky cervical cancer. Neoadjuvant chemotherapy reduces tumor volume and positivity of lymph nodes and thus minimizes the need for postoperative radiotherapy or chemoradiotherapy. Tumor size reduction and node negativity allows less radical surgical procedures such as modified radical hysterectomy or nerve-sparing radical hysterectomy. Early and especially late toxicity of our high-dose density chemotherapy is acceptable. Neoadjuvant chemotherapy followed by surgery represents a valid alternative to primary chemoradiotherapy in young and sexually active patients. Five-year survival in patients who underwent surgery in our study was 80.6%. Currently, 3 papers with 3 approaches have been published on NAC before fertility-sparing surgery. One of the limitations of fertility-preserving surgery is deep stromal invasion and tumors larger than 2 cm. The idea underlying NAC is to reduce the size of the cervical tumor to preserve fertility. In the present paper, we also review our experience with high-dose-density NAC in fertility-sparing surgery in 15 women (LAP3-NAC protocol).
Department of Obstetrics and Gynecology 2nd Medical Faculty Charles University Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12026677
- 003
- CZ-PrNML
- 005
- 20160307112137.0
- 007
- ta
- 008
- 120816s2010 xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1111/igc.0b013e3181f60d73 $2 doi
- 035 __
- $a (PubMed)21053526
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Robová, Helena $7 xx0110282 $u Department of Obstetrics and Gynecology, Second Medical Faculty, Charles University, Prague, Czech Republic
- 245 14
- $a The role of neoadjuvant chemotherapy and surgery in cervical cancer / $c H. Robova, M. Halaska, M. Pluta, P. Skapa, P. Strnad, J. Lisy, L. Rob
- 520 9_
- $a The role of neoadjuvant chemotherapy (NAC) in "bulky" and locally advanced cervical cancer has been of interest for the last 25 years, and in many countries, NAC has become the standard of care. In the present paper, we review our 10 years' experience with high-dose-density NAC in cervical cancer management in 141 women (CervNAC I protocol). High-dose-density neoadjuvant chemotherapy and radical surgery has resulted in high clinical response rates and seems to be feasible in the management of stage IB bulky cervical cancer. Neoadjuvant chemotherapy reduces tumor volume and positivity of lymph nodes and thus minimizes the need for postoperative radiotherapy or chemoradiotherapy. Tumor size reduction and node negativity allows less radical surgical procedures such as modified radical hysterectomy or nerve-sparing radical hysterectomy. Early and especially late toxicity of our high-dose density chemotherapy is acceptable. Neoadjuvant chemotherapy followed by surgery represents a valid alternative to primary chemoradiotherapy in young and sexually active patients. Five-year survival in patients who underwent surgery in our study was 80.6%. Currently, 3 papers with 3 approaches have been published on NAC before fertility-sparing surgery. One of the limitations of fertility-preserving surgery is deep stromal invasion and tumors larger than 2 cm. The idea underlying NAC is to reduce the size of the cervical tumor to preserve fertility. In the present paper, we also review our experience with high-dose-density NAC in fertility-sparing surgery in 15 women (LAP3-NAC protocol).
- 650 _2
- $a karcinom $x farmakoterapie $x patologie $x chirurgie $7 D002277
- 650 _2
- $a adjuvantní chemoterapie $7 D017024
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a fertilita $7 D005298
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hysterektomie $7 D007044
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a neoadjuvantní terapie $7 D020360
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a nádory děložního čípku $x farmakoterapie $x patologie $x chirurgie $7 D002583
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Halaška, Michael, $d 1947- $7 mzk2004258380 $u Department of Obstetrics and Gynecology, 2nd Medical Faculty of the Charles University, Prague, Czech Republic. mhalaska@centrum.cz
- 700 1_
- $a Pluta, Marek $7 xx0102087 $u Department of Gynecology and Obstet, Division of Oncogynecology, Charles University Prague, 2nd Medical Faculty, Prague 5, Czech Republic
- 700 1_
- $a Škapa, Petr $7 xx0105776 $u Department of Pathology and Molecular Medicine, Charles University, 2nd Medical School, University Hospital Motol, V Uvalu 84, 150 06, Prague 5, Czech Republic, petr.skapa@lfmotol.cuni.cz
- 700 1_
- $a Strnad, Pavel, $d 1951- $7 jn20011210213 $u Department of Obstetrics and Gynaecology, 2nd Medical Faculty, Charles University, Prague, Czech Republic
- 700 1_
- $a Lisý, Jiří, $d 1967- $7 mzk2004248612 $u Department of Imaging Methods, 2nd Medical Faculty, University Hospital Motol, Charles University, 150 06 Prague, Czech Republic
- 700 1_
- $a Rob, Lukáš, $d 1958- $7 xx0017807 $u Department of Obstetrics and Gynecology, 2nd Medical Faculty, Charles University, V uvalu 84, 150 00 Prague 5. lukas.rob@lfmotol.cuni.cz
- 773 0_
- $w MED00009896 $t International journal of gynecological cancer official journal of the International Gynecological Cancer Society $x 1525-1438 $g Roč. 20, č. 11 Suppl 2 (2010), s. S42-S46
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21053526 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20160307112154 $b ABA008
- 999 __
- $a ok $b bmc $g 948719 $s 784023
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 20 $c 11 Suppl 2 $d S42-S46 $i 1525-1438 $m International journal of gynecological cancer $n Int J Gynecol Cancer $x MED00009896
- LZP __
- $b NLK122 $a Pubmed-20120816/11/01
